이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Carasent 관리

관리 기준 확인 0/4

Carasent's CEO는 Daniel Ohman, Nov2022 에 임명되었습니다 의 임기는 1.58 년입니다. 는 € 263.27K 가치에 해당하는 회사 주식의 0.22% 직접 소유합니다. 263.27K. 경영진과 이사회의 평균 재임 기간은 각각 1.6 년과 1.7 년입니다.

주요 정보

Daniel Ohman

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.9yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2yrs
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

CEO

Daniel Ohman (44 yo)

1.9yrs

테뉴어

Mr. Daniel Ohman has been the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager...

리더십 팀

이름	위치	테뉴어	보상	소유권
Niclas Hugosson	Founder	no data	데이터 없음	3.53% NOK 4.0m
Svein Bjornstad	Chief Financial Officer	3.2yrs	데이터 없음	0.49% NOK 550.6k
Daniel Ohman	Chief Executive Officer	1.9yrs	데이터 없음	0.22% NOK 250.8k
Johan Eltes	Chief Technical Officer	2yrs	데이터 없음	데이터 없음
Jon Schultz	Legal Counsel	no data	NOK 45.00k	데이터 없음
Stefan Jernberg	Chief Compliance Officer	less than a year	데이터 없음	데이터 없음
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 447.18k	데이터 없음
Cornelia Broqvist	Chief Marketing Officer	2.1yrs	데이터 없음	데이터 없음
Anna Larsson	People and Culture Manager	no data	데이터 없음	데이터 없음
Vilma Jonson	Head of Strategy	1.1yrs	데이터 없음	0.033% NOK 37.6k

2.0yrs

평균 재임 기간

경험이 풍부한 관리: C34 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Tomas Meerits	Director	1.4yrs	데이터 없음	데이터 없음
Camilla Skoog	Independent Director	2.5yrs	데이터 없음	0.013% NOK 14.5k
Ulrika Sundling	Independent Director	2.5yrs	데이터 없음	0.028% NOK 31.1k
Petri Niemi	Independent Chairman of the Board	2yrs	데이터 없음	0.017% NOK 19.1k
Henric Carlsson	Independent Director	less than a year	데이터 없음	데이터 없음

2.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: C34 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Carasent 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Chief Executive Officer recently bought €121k worth of stock

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Recent updates

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령